ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC

Improved overall survival versus chemotherapy regardless of the PD - L1 tumor proportion score
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Conference News, Source Type: news